Introducing
  • Use is clinically shown to reduce A1C and increase time-in-range (1,2)

  • Easy to teach, learn, and use (1,3)

  • Preferred by people with diabetes and healthcare professionals (1)

MEALTIME INSULIN IS 
ALWAYS WITHIN REACH

2-Button Safety Mechanism

Ensures that dosing occurs only when intended—designed to prevent accidental dosing (5)

Adhesive Patch

Designed to keep the Patch on skin for up to 3 days

Buttons Lock To Notify

Stay in “squeezed” position when Patch is empty or cannula is occluded (5)

Water-Resistant

To a depth of 1 meter for up to 30 minutes

Tactile & Audible Feedback

Indicates 2-unit delivery (5)

Use Of CeQur Simplicity Is
Clinically Shown To Improve Glycemic Control (1,2)

After 24 Weeks With CeQur Simplicity, users increased time in range (TIR) by 50%. (2)

The International Consensus on Time In Range defines clinical target for TIR ≥ 70%, which is evidenced to be equivalent to an A1C ≤ 7%. (6)

Convenient

  • Fits into the lives of people requiring mealtime insulin dosing

  • Wearable while showering, sleeping, exercising, and swimming (5)

  • Easy to use (3)

Discreet

  • Worn and dosed under clothing

  • Compact design

  • Small (65x36 mm), lightweight (10 gm), and thin (<4 quarters thick)

  • Less embarrassment while dosing can lead to better adherence (1)

Injection-Free Dosing

  • Fewer injections

    • 1 Patch replaces 9 mealtime injections, for ~90 fewer injections per month

  • Less pain

    • 90% of users reported mealtime insulin painless with CeQur Simplicity (1)

CeQur Simplicity holds up to 200 units of rapid-acting insulin administered in 2-unit increments.

*Labeled for use with Humalog® U-100 and NovoLog® U-100. Insulin sold separately.

With Use Of CeQur Simplicity
A1C Target Goals Were Achieved (1)

Clinical Outcome Study Findings (1). Mean A1C was reduced to target goal by Week 24.

Results were comparable to pens. Consistent A1C <7% supports HEDIS Comprehensive Diabetes Care measure.

The convenient, discreet, 3-day, wearable insulin Patch for injection-free dosing

MEALTIME INSULIN IS ALWAYS WITHIN REACH

References:

  1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B on behalf of the Calibra Study Group. 2019. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with and Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.

  2. Johnson ML, Dreon DM, Levy BL, Richter S, Mullen D, Bergenstal R. 2018. Comparing Patch vs. Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles. Diabetes 2018 Jul; 67(Supplement 1)

  3. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association’s 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA.

  4. Peyrot M, Dreon D, Zraick V, Cross B, Tan MH. 2018. Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch. Diabetes Therapy. 9(1):297–307.

  5. Dreon D, Hannon T, Cross B, Carter B, Mercer N, Nguyen J, Tran A , Melendez P, Morales N, Nelson J, Tan M. 2018. Laboratory and Benchtop Performance of a Mealtime Insulin-Delivery System. Journal of Diabetes Science and Technology. 12(4):817-827.

  6. Battelino T, Danne T, Bergenstal R, Amiel S, Beck R, Biester T, Bosi E, Buckingham B, Cefalu W, Close K, Cobelli C, Dassau E, DeVries J, Donaghue K, Dovc K, Doyle F, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch I, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, LevineB, Mayorov A, Mathieu C, Murphy H, Nimri R, Nørgaard K, Parkin C, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer S, Phillip M. 2019. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care Aug 2019, 42 (8) 1593-1603

  7. Bohannon N, Bergenstal R, Cuddihy R, Kruger D, List S, Massaro E, Molich M, Raskin P, Remtema H, Strowig S, Whitehouse F, Brunelle R, Dreon D, Tan M. 2011. Comparison of a Novel Insulin Bolus-Patch with Pen/Syringe Injection to Deliver Mealtime Insulin for Efficacy, Preference, and Quality of Life in Adults with Diabetes: A Randomized, Crossover, Multicenter Study. Diabetes Technology & Therapeutics. 13(10):1031-1037.

Humalog® is a registered trademark of Eli Lilly and Company. NovoLog® is a registered trademark of Novo Nordisk A/S.

CeQur Simplicity Features

Simplify Mealtimes 
With A Click

CeQur Simplicity™ removes known barriers to mealtime dosing (4), such as inconvenience, embarrassment, and injection pain.

Real Stories From
Real People

Boyd Bush

CeQur Simplicity User
53 Years Old

CeQur Simplicity Is 
Designed For Safety

Introducing
  • Use is clinically shown to reduce A1C and increase time-in-range (1,2)

  • Easy to teach, learn, and use (1,3)

  • Preferred by people with diabetes and healthcare professionals (1)

MEALTIME INSULIN IS 
ALWAYS WITHIN REACH

2-Button Safety Mechanism

Ensures that dosing occurs only when intended—designed to prevent accidental dosing (5)

Adhesive Patch

Designed to keep the Patch on skin for up to 3 days

Buttons Lock To Notify

Stay in “squeezed” position when Patch is empty or cannula is occluded (5)

Water-Resistant

To a depth of 1 meter for up to 30 minutes

Tactile & Audible Feedback

Indicates 2-unit delivery (5)

CeQur Simplicity Is 
Designed For Safety

Users Prefer CeQur Simplicity

said they follow their insulin regimen better with CeQur Simplicity (3)

were satisfied with CeQur Simplicity (3)

asked to be switched from pen or syringe (7)

preferred CeQur Simplicity over pens (1)

CeQur Simplicity Encourages Adherence

Many people using CeQur Simplicity said they dosed in instances where they probably wouldn’t have dosed with a pen or syringe and stated they are likely to dose more often across meals, snacks, and correction boluses. (3)

Users Prefer CeQur Simplicity

said they follow their insulin regimen better with CeQur Simplicity (3)

were satisfied with CeQur Simplicity (3)

asked to be switched from pen or syringe (7)

preferred CeQur Simplicity over pens (1)

CeQur Simplicity Encourages Adherence

Many people using CeQur Simplicity said they dosed in instances where they probably wouldn’t have dosed with a pen or syringe and stated they are likely to dose more often across meals, snacks, and correction boluses. (3)

Get To Know
CeQur Simplicity Users
Learn how CeQur Simplicity works for people with diabetes. Hear their stories and their personal experiences. 
Get To Know
CeQur Simplicity Users
Learn how CeQur Simplicity works for people with diabetes. Hear their stories and their personal experiences. 

Boyd Bush

CeQur Simplicity User
53 Years Old